Latest Breaking News On - Agepha pharma - Page 4 : comparemela.com

FDA Approves First Anti-Inflammatory Drug for Heart Attack and Stroke Prevention

Colchicine, taken with or without statins, can lower the risk of heart attack, stroke, and death in adults with atherosclerosis.

Top in cardiology: FDA OKs gout drug to reduce CV events; studies support SGLT2 inhibitors

A 0.5 mg dose of colchicine, a drug commonly used for conditions such as gout, was recently approved by the FDA to prevent cardiovascular events in patients with residual inflammatory risk.It is the first anti-inflammatory agent to be approved as an atheroprotective CV treatment, according to a press release from the manufacturer, and is expected to be available later this year. News of the

'Striking' Benefit of Lipid Lowering in Primary Prevention

A new analysis has shown a particularly large reduction in CV events and death with lipid-lowering therapy in the primary prevention population, leading to calls for more attention to be paid to this group.

Low-Dose Colchicine Approved for CVD: Now What?

The FDA has given the new low dose of colchicine a broad indication for use in atherosclerotic cardiovascular disease, but how will the drug actually be used in clinical practice?

FDA Approves Colchicine for Decreasing CV Events